BIOCARTIS GROUP NV |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.29 EUR | +1.05% |
|
-.--% | -.--% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Biocartis Group NV specializes in the development of molecular diagnostic systems. Especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.
Net sales by source of income are mainly distributed between products sales (78.3%) and sale of collaboration services (19.3%; especially research and development services).
Calendar
2024-09-04
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.29
EUR
Average target price
1.1
EUR
Spread / Average Target
+279.31%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 28.98M | |
| +71.87% | 12.28B | |
| -19.76% | 8.08B | |
| +15.96% | 7.23B | |
| -6.42% | 5.29B | |
| +4.54% | 4.93B | |
| +18.62% | 4.19B | |
| -21.30% | 4.13B | |
| -40.48% | 2.24B | |
| -3.47% | 2B |
- Stock Market
- Equities
- BCART Stock
- News Biocartis Group NV
- Biocartis' Epidermal Growth Factor Receptor Mutation Test Shows Reduced Patient Management Decision Time
